EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Lopinavir and Ritonavir have High Affinity Toward the SARS-CoV-2 S-protein Receptor-binding Domain Sequenced in Brazil

Aline Diogo Marinho, Helyson Lucas Bezerra Braz, João Alison de Moraes Silveira, Danilo Galvão Rocha, Roberta Jeane Bezerra Jorge, Geanne Matos de Andrade

BIO Integration · 2025 · 6 (1)

DOI: 10.15212/bioi-2024-0055 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BIO Integration, 2025. Verfasst von Aline Diogo Marinho und 5 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first identified in China in December 2019, rapidly spread worldwide, resulting in the coronavirus disease 2019 (COVID-19) pandemic. Understanding the structural and functional interactions between the virus and host cells is critical for developing therapeutic strategies.

Methods

In this study, we employed in silico docking models to investigate the molecular interactions between the receptor-binding domain (RBD) of the SARS-CoV-2 spike glycoprotein, derived from the Brazilian genome sequence, and seven clinically approved drugs: umifenovir, darunavir, lopinavir, ritonavir, remdesivir, pirfenidone, and oseltamivir. The three-dimensional structure of the Omicron RBD model was generated through homology modeling, and potential active site cavities were predicted within the RBD structure.

Results

Among the seven drugs tested, only lopinavir and ritonavir demonstrated significant binding affinities to the RBD. Lopinavir exhibited a binding affinity of −9.8 kcal/mol, forming interactions with residues PHE168, GLY167, SER176, GLN175, GLU166, LEU134, LEU137, TYR171, PHE138, LEU174, and PHE172. Ritonavir showed a binding affinity of −8.9 kcal/mol, interacting with residues ARG148, ASN130, VAL23, SER81, ASN33, PHE29, TYR33, SER31, ASN132, ALA26, ALA30, ALA34, and TYR133.Molecular dynamics simulations confirmed the stability of the complexes formed between lopinavir and ritonavir and the RBD active site.

Conclusion

These findings underscore the potential of these protease inhibitors as therapeutic agents targeting the SARS-CoV-2 spike protein.

Zitieren

APA

Marinho, A. D., Braz, H. L. B., Silveira, J. A. D. M., Rocha, D. G., Jorge, R. J. B., & Andrade, G. M. D. (2025). Lopinavir and Ritonavir have High Affinity Toward the SARS-CoV-2 S-protein Receptor-binding Domain Sequenced in Brazil. BIO Integration, 6(1). https://doi.org/10.15212/bioi-2024-0055

Vancouver

Marinho AD, Braz HLB, Silveira JADM, Rocha DG, Jorge RJB, Andrade GMD. Lopinavir and Ritonavir have High Affinity Toward the SARS-CoV-2 S-protein Receptor-binding Domain Sequenced in Brazil. BIO Integration. 2025;6(1). doi:10.15212/bioi-2024-0055

BibTeX
@article{Marinho2025,
  author = {Marinho, Aline Diogo and Braz, Helyson Lucas Bezerra and Silveira, João Alison de Moraes and Rocha, Danilo Galvão and Jorge, Roberta Jeane Bezerra and Andrade, Geanne Matos de},
  title = {Lopinavir and Ritonavir have High Affinity Toward the SARS-CoV-2 S-protein Receptor-binding Domain Sequenced in Brazil},
  journal = {BIO Integration},
  year = {2025},
  volume = {6},
  number = {1},
  doi = {10.15212/bioi-2024-0055}
}
Kostenlos starten →